Clinical Research Directory
Browse clinical research sites, groups, and studies.
QLS1410 in Participants With Uncontrolled Hypertension
Sponsor: Qilu Pharmaceutical Co., Ltd.
Summary
The goal of this clinical trial is to measure the efficacy and safety of QLS1410 in participants with uncontrolled hypertension (uHTN) or treatment-resistant hypertension (rHTN). The main objective is to compare the difference in systolic blood pressure(SBP) change from baseline at Week 12 of treatment between participants receiving QLS1410 tablets and participants receiving placebo tablets.
Official title: A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of QLS1410 in Participants With Uncontrolled Hypertension
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
260
Start Date
2026-04
Completion Date
2027-03
Last Updated
2026-03-24
Healthy Volunteers
No
Conditions
Interventions
Dose 1 of QLS1410
QLS1410 tablet administered orally, once daily (QD).
Dose 2 of QLS1410
QLS1410 tablet administered orally, once daily (QD).
Dose 3 of QLS1410
QLS1410 tablet administered orally, once daily (QD).
placebo
Matching placebo tablet administered orally, once daily (QD).